Lv3
380 积分 2025-03-20 加入
Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
5小时前
已完结
Molecular Mechanisms of Quizartinib Response in FLT3-ITD Negative AML: An Updated Analysis from the Pethema Quiwi Trial
6天前
已关闭
Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
6天前
已完结
The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis
6天前
已完结
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG
20天前
已完结
The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis
20天前
已完结
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
20天前
已完结
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
20天前
已完结
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
20天前
已完结
The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis
22天前
已完结
皖公网安备34019202002308
